AVBP

Arrivent Biopharma, Inc. Health Care Pharmaceutical Preparations Russell 3000

$14.87Close $631.3MMarket cap $14.87 – $34.7452-week range Nov 9, 2026Next report

Highlights

Cautions

Not in an uptrend 1 of 8 trend conditions
Lagging the market RS 4 · weaker than 96% of stocks over 12 months
Far from its high 57% below its 52-week high
Results soon Nov 9, 2026, in 8 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 12, 2026

Off 12-month high 57%

1wk 29.2% price change

1mo 50.9% price change

12-month return 19% market up 11% · its own down 31%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.1× price / book

Earnings yield 30.3% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 59% return on equity

Free cash margin — -$160.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 12.4% $1.84 a day · 2×ATR $11.19

RS 4 / 99 vs the universe

Trend 1 / 8 trend template

Relative volume 0.9× vs 50-day average

Up/down volume 0.67 50 sessions

Implied move — no option chain · report Nov 9, 2026

Trend template · 1 of 8

150-day average above the 200-day: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 25.9% over the year, from 34m to 42m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 12, 2026

Last shock Oct 6, 2026-47% in one session21.8× volumeon an SEC filing-1% since

Financials

3 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$166.3M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$160.6M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 42.45m +1446.3% since FY2023

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$74.6M	-$94.3M	-$177.5M
Net income	-$69.3M	-$80.5M	-$166.3M
Earnings per share	-$32.38	-$2.56	-$4.32
Free cash flow	-$55.8M	-$70.2M	-$160.6M
Cash	$150.4M	$74.3M	$45.5M
Shareholders' equity	-$153.2M	$257.7M	$307.2M
Shares outstanding	2.75m	33.71m	42.45m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 12, 2026	Quarterly ↗	Jun 30, 2026	43d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Mar 5, 2026	Annual ↗	Dec 31, 2025	64d
Nov 10, 2025	Quarterly ↗	Sep 30, 2025	41d
Aug 11, 2025	Quarterly ↗	Jun 30, 2025	42d
May 12, 2025	Quarterly ↗	Mar 31, 2025	42d
Mar 3, 2025	Annual ↗	Dec 31, 2024	62d
Nov 14, 2024	Quarterly ↗	Sep 30, 2024	45d
Aug 14, 2024	Quarterly ↗	Jun 30, 2024	45d
May 8, 2024	Quarterly ↗	Mar 31, 2024	38d

Current reports

Filed	Disclosed
Oct 26, 2026	Regulation FD · Other events ↗
Oct 19, 2026	Regulation FD ↗
Oct 13, 2026	Regulation FD · Other events ↗
Oct 6, 2026	Regulation FD · Other events ↗
Aug 12, 2026	Material agreement · Results ↗
Jun 22, 2026	Shareholder vote ↗
May 11, 2026	Other events ↗
May 11, 2026	Results ↗
Mar 17, 2026	Regulation FD · Other events ↗
Mar 5, 2026	Results ↗
Nov 10, 2025	Results ↗
Sep 9, 2025	Regulation FD · Other events ↗